Do components of metabolic syndrome contribute to cardiac autonomic neuropathy in non-diabetic patients?

Saudi Medical Journal

Volumn 31, Issue 6, 2010, Pages 650-657

  Rasic Milutinovic, Zorica R ^a   Milicevic, Dusan R ^a   Milovanovic, Branislav D ^a   Perunicic Pekovic, Gordana B ^a   Pencic, Biljana D ^a  

^a University Clinical Center   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE MONITORING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC DIET; DIABETIC PATIENT; DIET THERAPY; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HAND GRIP; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; SERBIA; WAIST CIRCUMFERENCE; AGED; DIABETIC NEUROPATHY; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 77958048542     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Viner RM, Segal TY, Lichtarowicz-Krynska E, Hindmarsh P. Prevalence of the insulin resistance syndrome in obesity. Arch Dis Child 2005; 90: 10-14.
2. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
3. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481.
4. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 2007; 21: 1443-1455.
5. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307: 384-387.
6. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
7. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
8. Oda E, Kawai R. Significance of heart rate in the prevalence of metabolic syndrome and its related risk factors in Japanese. Circ J 2009; 73: 1431-1436.
9. Stein PK, Barzilay JI, Domitrovich PP, Chaves PM, Gottdiener JS, Heckbert SR, et al. The relationship of heart rate and heart rate variability to non-diabetic fasting glucose levels and the metabolic syndrome: the Cardiovascular Health Study. Diabet Med 2007; 24: 855-863.
10. Flaa A, Aksnes TA, Kjeldsen SE, Eide I, Rostrup M. Increased sympathetic reactivity may predict insulin resistance: an 18-year follow-up study. Metabolism 2008; 57: 1422-1427.
11. Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 2007; 101: 27-39.
12. Carnethon MR, Jacobs DR Jr, Sidney S, Liu K; CARDIA study. Influence of autonomic nervous system dysfunction on the development of type 2 diabetes: the CARDIA study. Diabetes Care 2003; 26: 3035-3041.
13. Grassi G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Seravalle G, et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005; 48: 1359-1365.
14. Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ. Effects of dietary weight loss on sympatheticactivity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab 2005; 90: 5998-6005.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-24897.
16. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985; 8: 491-498.
17. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996; 17: 354-381.
18. Huggett RJ, Hogarth AJ, Mackintosh AF, Mary DA. Sympathetic nerve hyperactivity in non-diabetic offspring of patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2741-2744.
19. Mary DA, Stoker JB. The activity of single vasoconstrictor nerve units in hypertension. Acta Physiol Scandinav 2003; 177: 367-376.
20. Goldfine AB, Kahn CR. Adiponectin: linking the fat cell to insulin sensitivity. Lancet 2003; 362: 1431-1432.
21. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56: 45-62.
22. Lucini D, Cusumano G, Bellia A, Kozakova M, Difede G, Lauro R, et al. Is reduced baroreflex gain a component of the metabolic syndrome? Insights from the LINOSA study. J Hypertens 2006; 24: 361-370.
23. Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E, et al. Obesity and metabolic syndrome in circadian Clock mutant mice. Science 2005; 308: 1043-1045.
24. Sarafidis PA, Bakris GL.The antinatriuretic effect of insulin: an unappreciated mechanism for hypertension associated with insulin resistance? Am J Nephrol 2007; 27: 44-54.
25. Anan F, Takahashi N, Ooie T, Yufu K, Saikawa T, Yoshimatsu H. Role of insulin resistance in nondipper essential hypertensive patients. Hypertens Res 2003; 26: 669-676.
26. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesityrelated hypertension. Hypertension 2006; 48: 787-796.
27. Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MC, et al. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophys Res Commun 2002; 296: 293-299.
28. Haluzik MM, Haluzik M. PPAR-alpha and insulin sensitivity. Physiol Res 2006; 55: 115-222.
29. Shinozaki K, Ayajiki K, Nishio Y, Sugaya T, Kashiwagi A, Okamura T. Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension 2004; 43: 255-262.
30. Schroeder EB, Chambless LE, Liao D, Prineas RJ, Evans GW, Rosamond WD, et al. Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2005; 28: 668-674.